• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Kiniksa Pharmaceuticals Ltd.

    2/12/24 6:06:38 AM ET
    $KNSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KNSA alert in real time by email
    SC 13G 1 tm245464d9_sc13g.htm SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

     

     

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Kiniksa Pharmaceuticals, Ltd.

     

    (Name of Issuer)

     

    Class A Common Shares, $0.000273235 par value per share

     

    (Title of Class of Securities)

     

    G5269C101

     

    (CUSIP Number)

     

    December 31, 2023

     

    (Date of event which requires filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

     

    x  Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    (Page 1 of 8 Pages)

     

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes)

     

     

     

     

     

    CUSIP No. G5269C101

     

    13G Page 2 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Rubric Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    State of Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,907,501 Class A Common Shares

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,907,501 Class A Common Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,907,501 Class A Common Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.21%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

     

     

    CUSIP No. G5269C101

     

    13G Page 3 of 8 Pages

     

    1

    NAMES OF REPORTING PERSONS

    David Rosen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3

    SEC USE ONLY

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States of America

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,907,501 Class A Common Shares

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,907,501 Class A Common Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,907,501 Class A Common Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.21%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

    CUSIP No. G5269C101

     

    13G Page 4 of 8 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Kiniksa Pharmaceuticals, Ltd. (the "Issuer").
       
    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Issuer's principal executive offices are located at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:
       
      (i) Rubric Capital Management LP ("Rubric Capital"), the investment adviser to certain investment funds and/or accounts (collectively, the "Rubric Funds") that hold the f Class A Common Shares (as defined in Item 2(d) below) reported herein; and
         
      (ii) David Rosen ("Mr. Rosen"), Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital.
         
      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the principal business office of each of the Reporting Persons is 155 East 44th St, Suite 1630, New York, NY 10017.
       
    Item 2(c). CITIZENSHIP:
       
      Rubric Capital is a Delaware limited partnership. Mr. Rosen is a citizen of the United States of America.
       
    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Class A Common Shares, $0.000273235 par value per share (the "Class A Common Shares").
       
    Item 2(e). CUSIP NUMBER:
       
      G5269C101

     

     

     

     

    CUSIP No. G5269C101

     

    13G Page 5 of 8 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
           
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
           
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
           
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
           
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
           
      (g) x Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
           
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
           
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
           
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:                                    

       
    Item 4. OWNERSHIP.
       
     

    The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.

     

    The percentage set forth in Row (11) of the cover page for each of the Reporting Persons is based on the 35,409,710 Class A Common Shares outstanding as of October 27, 2023, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the Securities and Exchange Commission on November 2, 2023.

       
    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.
       
    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2. Rubric Capital Master Fund LP, a Rubric Fund, has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Class A Common Shares.

     

     

     

     

    CUSIP No. G5269C101

     

    13G Page 6 of 8 Pages

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.
       
    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.
       
    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.
       
    Item 10. CERTIFICATION.
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below the Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. G5269C101

     

    13G Page 7 of 8 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of our knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    DATED: February 12, 2024  
       
    RUBRIC CAPITAL MANAGEMENT LP  
       
    By: /s/ Michael Nachmani  
    Name: Michael Nachmani  
    Title: Chief Operating Officer  
       
    /s/ David Rosen  
    DAVID ROSEN  

     

     

     

     

    CUSIP No. G5269C101

     

    13G Page 8 of 8 Pages

     

    EXHIBIT 1

     

    JOINT ACQUISITION STATEMENT
    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    DATED: February 12, 2024  
       
    RUBRIC CAPITAL MANAGEMENT LP  
       
    By: /s/ Michael Nachmani  
    Name: Michael Nachmani  
    Title: Chief Operating Officer  
       
    /s/ David Rosen  
    DAVID ROSEN  

     

     

     

    Get the next $KNSA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KNSA

    DatePrice TargetRatingAnalyst
    3/13/2025$40.00Buy
    Citigroup
    9/13/2024$40.00Buy
    Jefferies
    5/3/2024$34.00Overweight
    Wells Fargo
    12/29/2021$37.00 → $34.00Buy
    B of A Securities
    More analyst ratings

    $KNSA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

      – Pearce joins NHL Hall-of-Famer, Henrik Lundqvist, to educate patients and caregivers about the importance of accurate and early diagnosis of recurrent pericarditis, a chronic autoinflammatory disease of the heart that is often underdiagnosed or misdiagnosed – LONDON, April 30, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, has partnered with Country Music Association, Academy of Country Music, and GRAMMY Award-winning country star, Carly Pearce, to share her personal experience with recurrent

      4/30/25 8:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

      – ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, w

      4/29/25 7:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

      LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and

      4/24/25 4:01:00 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF COMMERCIAL OFFICER Moat Ross exercised 10,122 units of Class A Ordinary Share at a strike of $17.76 and sold $283,416 worth of Class A Ordinary Share (10,122 units at $28.00) (SEC Form 4)

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      5/5/25 4:54:51 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF OPERATING OFFICER Tessari Eben

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      5/5/25 4:53:14 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CHIEF ACCOUNTING OFFICER Megna Michael R

      4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)

      5/5/25 4:52:19 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Financials

    Live finance-specific insights

    See more
    • Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

      – ARCALYST® (rilonacept) Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, w

      4/29/25 7:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025

      LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and

      4/24/25 4:01:00 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

      – ARCALYST® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis expected to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Abiprubart development in Sjögren's Disease to be discontinued –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) (Kiniksa), a biopharmaceutical company developing and c

      2/25/25 7:30:00 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    SEC Filings

    See more
    • SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

      144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      5/7/25 5:13:12 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Kiniksa Pharmaceuticals International plc

      144 - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      5/7/25 4:00:34 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Kiniksa Pharmaceuticals International plc

      10-Q - Kiniksa Pharmaceuticals International, plc (0001730430) (Filer)

      4/29/25 4:15:30 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Citigroup initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

      3/13/25 7:43:42 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Jefferies initiated coverage of Kiniksa Pharmaceuticals with a rating of Buy and set a new price target of $40.00

      9/13/24 7:34:05 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Kiniksa Pharmaceuticals with a new price target

      Wells Fargo initiated coverage of Kiniksa Pharmaceuticals with a rating of Overweight and set a new price target of $34.00

      5/3/24 11:21:30 AM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KNSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/14/24 4:32:31 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/14/24 4:15:22 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kiniksa Pharmaceuticals International plc

      SC 13G/A - Kiniksa Pharmaceuticals International, plc (0001730430) (Subject)

      11/13/24 4:30:25 PM ET
      $KNSA
      Biotechnology: Pharmaceutical Preparations
      Health Care